Maximum tolerated dose [clinicaltrials_resource:e0b5aca92a5d5a42adf3def4f06e8273]
Patients receive topotecan intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 6 patients will be treated at the MTD.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Maximum tolerated dose [clinicaltrials_resource:e0b5aca92a5d5a42adf3def4f06e8273]
Patients receive topotecan intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 6 patients will be treated at the MTD.
Bio2RDF identifier
e0b5aca92a5d5a42adf3def4f06e8273
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:e0b5aca92a5d5a42adf3def4f06e8273
measure [clinicaltrials_vocabulary:measure]
Maximum tolerated dose
description
Patients receive topotecan int ...... ts will be treated at the MTD.
identifier
clinicaltrials_resource:e0b5aca92a5d5a42adf3def4f06e8273
title
Maximum tolerated dose
@en
type
label
Maximum tolerated dose [clinicaltrials_resource:e0b5aca92a5d5a42adf3def4f06e8273]
@en